Mission:
Contributes to transition:
Contributes to SDG(s):
Phosphoenix is developing a brain implant (neuroprosthesis system) that uses AI to restore functional sight in people who have gradually gone blind later in life. Normally, visual information travels from the eye to the retina and then via the visual pathway to the brain. Phosphoenix's technology bypasses the eye and directly activates the brain. At the heart of the Phosphoenix neuroprosthesis system is the Fountain Probe™, an implant developed by the company that sends electrical signals to a visual brain area, the lateral geniculate nucleus (LGN). This generates phosphenes: light phenomena or visual perceptions that a person can perceive. In this way, an artificial form of sight is generated.
Investment manager Sara Schaafsma: “Phosphoenix is developing a potentially life-changing technology for people with severe blindness. In the future, the technology could potentially offer them greater self-reliance and help them to actively participate in society with less support. We are impressed by the combination of strong science, clear clinical relevance and the progress the team is making towards clinical validation. With its roots in Amsterdam, via the Netherlands Institute for Neuroscience, Phosphoenix is also an excellent example of how scientific innovation from our region can lead to societal impact. We are therefore delighted to support this company in preparing for its first human study.”
Greencovery has a sustainable solution to reuse residual streams from the food industry and convert them into valuable ingredients. In this way, a cost item, waste processing of residual materials, is transformed into an extra...
Phoenix Metals is an innovative company that recovers valuable raw materials from industrial waste streams such as steel slag, thereby playing an innovative role in the battery market.
Root Sustainability develops AI technology that allows retailers to make smart decisions based on product-specific data to concretely reduce the CO2 footprint in their supply chain. Dispersed data is quickly and efficiently...
Methotrexate is currently the most commonly prescribed basic drug for rheumatoid arthritis worldwide. Sixty to eighty per cent of patients receive this drug. The problem, however, is that methotrexate is too...
Healthplus.ai is a Dutch MedTech scale-up from Amsterdam. Their AI system PERISCOPE® calculates each patient's risk of infection after surgery and gives the healthcare team clear actions to reduce that risk....
Subscribe to our newsletter and stay up to date with news, stories, relevant events and more.
